Peter Sillevis Smitt
Department of Neurology
Erasmus University Medical Center
Room H639
’s-Gravendijkwal 230
3015 CE Rotterdam
Tel. 010 - 703 3327
Fax. 010 - 703 2156
e-mail: p.sillevissmitt@erasmusmc.nl
website: www.erasmusmc.nl
Prof. Sillevis Smitt finished his residency and PhD-thesis in 1992 at the University of Amsterdam. After a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center (Prof. J. Posner) he became staff neurologist at the Neuro-oncology Department of the Daniel den Hoed Cancer Center in 1995. In 2002 he became head of the Neurology department of the Erasmus University Medical Center. He is also Head of the Laboratory of Neuro-oncology that was founded in 1998. The Erasmus MC includes the Daniel den Hoed Cancer Clinic, the Academic Hospital, the Sophia Children's Hospital and the Medical Faculty of the Erasmus University Rotterdam. Besides paraneoplastic neurological syndromes, his main research interest is in experimental brain tumor treatment, including gene therapy.
Scientific Team
His collaborators are: Marieke de Graaf, MD, working in the Medical and Tumor Immunology Laboratary and the Neuro-oncology Lab.; Dr. Jan Willem Gratama, PhD, Head of the Tumor Immunology Laboratory; Prof. Herbert Hooijkaas, MD, PhD, an Immunologist in charge of the Immunology Laboratory who supervises routine testing for known paraneoplastic antineuronal autoantibodies; Theo Luider, PhD, biochemist specialized in mass spectrometry; Ing. Esther Hulsenboom, technician working in the Neuro-oncology Lab; and Ing. Eric Brouwer, technician working in the Neuro-oncology Lab.
Laboratory Research facilities
Immunohistochemistry and immunoblot techniques to detect onconeural antibodies. Protein purification, PCR, RT-PCR, in situ hybridization and gene cloning.
Areas of interest:
- clinical: PCD and Hodgkin's disease (with or without antibodies) Oculomotor abnormalities in PNS
- Preclinical: Atypical staining of Purkinje cells; HuD specific T-lymphocytes
- Animal models of antibody mediated neurological disorders
Selected Publications:
1. Shams'ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, Van't Veer M, Sillevis Smitt P. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253:16-20.
2. Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, Vecht C, Sillevis Smitt P. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126:1409-18.
3. Sillevis Smitt P, Grefkens J, De Leeuw B, Van Den Bent M, Van Putten W, Hooijkaas H, Vecht C. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249:745-53.
4. Sillevis Smitt P, Kinoshita A, DeLeeuw B, Moll W, Coesmans M, Jaarsma D, Henzen-Logmans S, Vecht C, De Zeeuw C, Sekiyama N, Nakanishi S, Shigemoto R. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. New Engl J Med 2000; 342:21-27.
5. Coesmans M, Sillevis Smitt PA, Linden DJ, Shigemoto R, Hirano T, Yamakawa Y, Van Alphen AM, Luo C, Van Der Geest JN, Kros JM, Gaillard CA, Frens MA, De Zeeuw CI. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 2003; 53:325-36.
6. de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist 2006; 11:292-305.
|
